• Vaccine Name: A986 + MPL/QS21
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: A986 is a recombinant multistage fusion protein composed of Ag85A, Rv2028c, Rv2029c, and Rv3126c (Chen et al., 2024).
• FbpA (Ag85A) gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation (Chen et al., 2024).
  • Detailed Gene Information: Click Here.
• Rv2028c gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Chen et al., 2024).
  • Detailed Gene Information: Click Here.
• pfkB gene engineering:
  • Type: Fusion Portein
  • Description: This is use in fusion protein preparation (Chen et al., 2024).
  • Detailed Gene Information: Click Here.
• Rv3126c gene engineering:
  • Type: Fusion Portein
  • Description: Use in fusion protein preparation (Chen et al., 2024).
  • Detailed Gene Information: Click Here.
• Preparation: The A986 fusion protein was recombinantly expressed and purified, then formulated with the MPL/QS21 adjuvant prior to subcutaneous administration as a booster vaccine following BCG priming (Chen et al., 2024).
• Immunization Route: subcutaneous injection
• Description: A986 + MPL/QS21 is a multistage recombinant fusion protein tuberculosis vaccine composed of Ag85A, Rv2028c, Rv2029c, and Rv3126c, formulated with MPL/QS21 adjuvant and administered as a booster following BCG priming to enhance protective immunity against Mycobacterium tuberculosis (Chen et al., 2024).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were primed with a single subcutaneous injection of 5 × 10⁶ CFU BCG at week −8, followed by three subcutaneous booster doses of 10 μg A986 formulated with 5 μg MPL/QS21 administered at two-week intervals, and subsequently challenged with aerosolized Mycobacterium tuberculosis H37Rv (Chen et al., 2024).
• Challenge Protocol: Vaccinated mice were challenged with aerosolized Mycobacterium tuberculosis H37Rv at approximately 100 CFU, and bacterial burden was measured in the lungs and spleen (Chen et al., 2024).
• Efficacy: A986 + MPL/QS21, when used as a BCG booster, significantly reduced lung bacterial burden compared with BCG alone, demonstrating enhanced protective efficacy in a mouse model (Chen et al., 2024).
• Description: Vaccination with A986 + MPL/QS21 induced strong Th1-type immune responses characterized by increased IFN-?, TNF-?, and IL-2 production, enhanced CD4? T-cell activation, and improved memory T-cell formation compared with controls (Chen et al., 2024).
• Information about this animal model: Mouse Model for TB research